AlphaValue Corporate Services
COVERAGE ABOUT US CONTACT FR
This research has been commissioned and paid for by the company and is deemed to constitute an acceptable minor non-monetary benefit as defined in MiFID II

Crossject

CR 		Bloomberg   ALCJ FP
Supergenerics  /  France  Web Site   |   Investors Relation
Things get going
Target
Upside 435%
Price (€) 2.13
Target Price (€) 11.4
Market Cap (€M) 77.8
Perf. 1W: 2.65%
Perf. 1M: -36.2%
Perf. 3M: -59.2%
Perf Ytd: -57.1%
10 day relative perf. to stoxx600: -1.42%
20 day relative perf. to stoxx600: -35.4%
EPS change18/08/2021
Download

Change in EPS2021 : € 0.18 vs 0.18-0.32%
2022 : € 0.91 vs 0.91-0.32%

We have only integrated the detailed numbers for FY20, which translate into a slightly lower EPS. However, the change is not meaningful given the still very low level of results of the company before its products reach the market.
Updates
.